Skip to main content
. Author manuscript; available in PMC: 2011 Jul 15.
Published in final edited form as: Cancer Res. 2010 Jun 29;70(14):6083–6092. doi: 10.1158/0008-5472.CAN-09-4736

Figure 2. Increased frequency of p53 deletions in CD19-cre+/Dicerfl/fl/Eμ-myc lymphomas.

Figure 2

(A) Protein lysates of lymphomas from CD19-cre+/Dicerfl/fl/Eμ-myc transgenic mice were subjected to Western blot analysis for p53, ARF, Mdm2, and β-actin. Protein lysates from p53/Mdm2-double null MEFs and a B cell lymphoma containing mutant p53 were used as controls. (B) Southern blots for p53 and ARF of lymphomas from CD19-cre+/Dicerfl/fl/Eμ-myc transgenic mice. Asterisks denote lymphomas that have deleted p53 and ARF. Lymphomas that contain p53 or ARF (plus signs) or that have deleted p53 (p53 Del) or ARF (ARF Del) are denoted.